Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP221426.RASXpoHQakKy8WrcPLSlAuB7zHyIqxzU8Zq2rPQZgjrFQ130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP221426.RASXpoHQakKy8WrcPLSlAuB7zHyIqxzU8Zq2rPQZgjrFQ130_assertion type Assertion NP221426.RASXpoHQakKy8WrcPLSlAuB7zHyIqxzU8Zq2rPQZgjrFQ130_head.
- NP221426.RASXpoHQakKy8WrcPLSlAuB7zHyIqxzU8Zq2rPQZgjrFQ130_assertion description "[KRAS mutations are one of the most common driver mutations in non-small-cell lung cancer (NSCLC) and finding druggable target molecules to inhibit oncogenic KRAS signaling is a significant challenge in NSCLC therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP221426.RASXpoHQakKy8WrcPLSlAuB7zHyIqxzU8Zq2rPQZgjrFQ130_provenance.
- NP221426.RASXpoHQakKy8WrcPLSlAuB7zHyIqxzU8Zq2rPQZgjrFQ130_assertion evidence source_evidence_literature NP221426.RASXpoHQakKy8WrcPLSlAuB7zHyIqxzU8Zq2rPQZgjrFQ130_provenance.
- NP221426.RASXpoHQakKy8WrcPLSlAuB7zHyIqxzU8Zq2rPQZgjrFQ130_assertion SIO_000772 22964644 NP221426.RASXpoHQakKy8WrcPLSlAuB7zHyIqxzU8Zq2rPQZgjrFQ130_provenance.
- NP221426.RASXpoHQakKy8WrcPLSlAuB7zHyIqxzU8Zq2rPQZgjrFQ130_assertion wasDerivedFrom befree-20140225 NP221426.RASXpoHQakKy8WrcPLSlAuB7zHyIqxzU8Zq2rPQZgjrFQ130_provenance.
- NP221426.RASXpoHQakKy8WrcPLSlAuB7zHyIqxzU8Zq2rPQZgjrFQ130_assertion wasGeneratedBy ECO_0000203 NP221426.RASXpoHQakKy8WrcPLSlAuB7zHyIqxzU8Zq2rPQZgjrFQ130_provenance.